The human induced pluripotent stem cell (iPSc) technology is a powerful tool to create unique human disease-relevant models, to study molecular and cellular pathological mechanisms, and for drug screening approaches.

The Brain and Spine Institute (ICM, Paris) acquired this technology in 2013 in order to promote forefront basic and preclinical research programs for neurodegenerative diseases. Today the core facility CELIS-iPS proposes the generation and the genetic engineering of human iPS cells to internal research teams, external academic teams and industrial partners. The IHU-A-ICM funding supports this activity.



  • Generation of human iPSc with Sendai vectors from human fibroblasts and from blood cells
  • Full molecular and functional characterization of iPSc clones (SNP Array, mycoplasmas, Immunofluorescence, Scorecard…)
  • Genetic engineering of human iPSc with the CRISPR/CAS9 technology (NHEJ or HR)
  • Generation of human iPS-derived neural stem cells
  • Theoretical and practical learning sessions on human iPSc culture
  • Access to a L2 cell culture box equipped for iPSc culture